These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2119524)

  • 1. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.
    Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J
    Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.
    Haimovich J; Davis HM; Schreiber AB
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ; Lusher JM; Cohen AR; Salzman P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates.
    Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM
    Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies to human procoagulant factor VIII.
    Rotblat F; Goodall AH; O'Brien DP; Rawlings E; Middleton S; Tuddenham EG
    J Lab Clin Med; 1983 May; 101(5):736-46. PubMed ID: 6403638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on a monoclonal antibody to human factor viii coagulant activity, with a description of a facile two-site factor VIII coagulant antigen assay.
    Brown JE; Thuy LP; Carton CL; Hougie C
    J Lab Clin Med; 1983 May; 101(5):793-805. PubMed ID: 6403639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunoglobulins in hemophilia: correlation between IgG subclasses, IgE and HIV antibody.
    Kumar A; Gera R; Kulkarni R; Hogrefe WR; Kaufman DB
    J Clin Lab Immunol; 1990 Apr; 31(4):157-60. PubMed ID: 1967059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
    Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
    Nilsson IM; Berntorp E; Zettervall O
    N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of factor VIII for surgery and major bleeding.
    Hay CR; Doughty HI; Savidge GF
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S15-9. PubMed ID: 8735792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.
    Schulman S; Varon D; Keller N; Gitel S; Martinowitz U
    Thromb Haemost; 1994 Sep; 72(3):403-7. PubMed ID: 7855792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
    Perret BA; Poorbeik M; Morell A
    Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N; Karges HE; Weidmann E
    Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of proteolytic antibodies against factor VIII in hemophilia A.
    Lacroix-Desmazes S; Bayry J; Misra N; Horn MP; Villard S; Pashov A; Stieltjes N; d'Oiron R; Saint-Remy JM; Hoebeke J; Kazatchkine MD; Reinbolt J; Mohanty D; Kaveri SV
    N Engl J Med; 2002 Feb; 346(9):662-7. PubMed ID: 11870243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.